In 2025, Sanofi demonstrated impressive business and financial performance despite challenges in the global pharmaceutical industry. According to the company's Q4 and full-year 2025 financial results, Sanofi made positive strides in sales, profitability, and pipeline innovation. Revenue for the year grew by 9.9% at constant exchange rates (CER), reaching €43.63 billion, while the business earnings per share (EPS) increased by 15.0% to €7.83. This success was driven by strong sales of core products like Dupixent, successful new product launches, and rigorous cost control. CEO Paul Hudson highlighted that the company’s focus on optimizing its product portfolio and making strategic investments has laid the foundation for long-term profitable growth. This article will provide a comprehensive analysis of Sanofi's 2025 performance, including financial results, product performance, pipeline progress, capital allocation, and sustainability.
Sanofi’s financial data in 2025 reflected the success of its "profitable growth" strategy. Fourth-quarter sales totaled €11.30 billion, a 13.3% increase compared to the previous year, based on constant exchange rates. For the full year, sales reached €43.63 billion, growing by 9.9%. This growth was mainly driven by the U.S. market (up 16.3% year-over-year), as well as moderate growth in Europe and other regions. It is worth noting that exchange rate fluctuations had a negative impact on sales (actual growth was only 6.2% for the year), but the company mitigated part of this impact through product portfolio adjustments.
In terms of profitability, the gross margin improved to 77.5% (up 1.8 percentage points from 2024), reflecting a higher share of high-margin specialty drugs. In Q4, the operating income (BOI) was €2.34 billion, a 21.7% increase year-over-year. For the full year, operating income reached €12.15 billion, up 11.9%. The improvement in operating margin was driven by revenue growth leverage and cost discipline—R&D expenses grew by 8.8%, while selling and administrative expenses rose by 7.3%, both below the sales growth rate. The business EPS for the year rose by 15.0% to €7.83, highlighting enhanced shareholder returns. Free cash flow for the year amounted to €8.09 billion, a significant increase from 2024, supporting the company’s ability to invest and pay dividends.
In terms of regional performance, the U.S. market accounted for the largest share of sales (€22.18 billion, up 16.3% year-over-year), mainly driven by Dupixent and new product launches. The European market had sales of €9.17 billion, growing by 1.6%, while sales in other regions totaled €12.28 billion, an increase of 5.6%. In China, the market contributed €2.62 billion, up 2.0%. Despite exchange rate pressures and market challenges, Sanofi maintained resilience through product innovation and regional diversification.
Sanofi’s product portfolio performed strongly in 2025, particularly in immunology, rare diseases, and vaccines. Dupixent (dupilumab), the company’s flagship product, generated €15.71 billion in sales, a 25.2% increase. In Q4, it surpassed €4 billion in sales for two consecutive quarters. Dupixent maintained its leadership in multiple indications, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and newly launched indications like chronic spontaneous urticaria (CSU) and chronic obstructive pulmonary disease (COPD). In the U.S., Dupixent was the most prescribed biologic by dermatologists, pulmonologists, and allergists, reflecting its clinical value.
New product launches became a key growth engine. In 2025, sales of new drugs and vaccines reached €5.72 billion, up 34.0%. Notably, the sales of ALTUVIIIO (for hemophilia A) reached €1.16 billion, a 77.6% increase, making it a new blockbuster product. Other new products such as Nexviazyme (for Pompe disease), Sarclisa (for multiple myeloma), and Qfitlia (for hemophilia) contributed additional sales in their first year. Additionally, newly approved products like Wayrilz (for immune thrombocytopenia) and Nuvaxovid (COVID-19 vaccine) also made sales contributions, demonstrating the efficiency of pipeline conversion.
The vaccine business saw a 2.5% decline in Q4, but the full-year performance exceeded expectations. Flu vaccine sales grew by 31.5% in Q4, driven by epidemiological factors and improved vaccination rates. Beyfortus (RSV vaccine) generated €1.78 billion in sales, a 9.5% increase, and was launched in 45 countries. However, sales of the combined polio/pertussis/Hib vaccine declined by 4.4%, primarily due to a global decline in birth rates.
In terms of legacy products, Lantus (insulin) and Toujeo (diabetes treatment) grew by 10.3% and 12.0%, respectively. However, sales of older drugs like Aubagio declined by 35.4% due to patent expiration. The company streamlined its product portfolio and focused its resources on high-growth areas.
In 2025, Sanofi made significant breakthroughs in its R&D pipeline, which will drive future growth. The company published results from 12 phase III clinical trials, reported data from 15 phase II trials, and advanced 10 new molecules into clinical development, including three gene therapies. Regulatory milestones included 10 new drug approvals across immunology, rare diseases, and vaccines.
Key pipeline highlights included:
Dupixent: New indication for allergic fungal rhinosinusitis (AFRS) met its primary endpoint in phase III trials. The U.S. FDA has accepted the priority review for AFRS, with approval expected in February 2026. Additionally, Dupixent was approved for pediatric asthma in Japan and for CSU in the EU.
Amlitelimab (OX40L monoclonal antibody): Positive phase III results for atopic dermatitis (AD) were observed in studies COAST 1, COAST 2, and SHORE. Efficacy increased with longer treatment duration, and it showed good tolerability. Global filing is expected in the second half of 2026.
Tzield/Teizeild (teplizumab): Approved in the EU for delaying the progression of type 1 diabetes (T1D), becoming the first disease-modifying therapy. The U.S. FDA is prioritizing its review for expansion to pediatric patients.
In terms of acquisitions and collaborations, Sanofi completed the acquisition of Vicebio, bringing in RSV/HMPV vaccine candidates, and announced the acquisition of Dynavax to enhance its adult vaccine portfolio, expected to close in Q1 2026. In the rare disease space, the company received approval for Cerezyme for Gaucher disease type 3 and Cablivi for acquired thrombotic thrombocytopenic purpura in China.
In 2025, Sanofi actively executed its capital allocation policy, balancing investment with shareholder returns. The company completed a €5 billion share buyback program and proposed a €4.12 per share dividend, a 5.1% increase, marking 31 consecutive years of dividend growth. These actions reflected strong cash flow generation and a commitment to shareholder value.
Strategic investments included the net proceeds of €10.4 billion from the Opella deal, which were used for business development and external innovation, such as the acquisition of Dynavax (€2.2 billion). The company plans to execute a €1 billion share repurchase in 2026, while maintaining an AA credit rating to ensure financial flexibility. On the balance sheet, net debt increased from €8.77 billion in 2024 to €11.01 billion, mainly due to acquisitions, but the company’s cash reserves remain healthy.
Sanofi is recognized as an industry leader in Environmental, Social, and Governance (ESG) initiatives. The company was named to the CDP Climate Change A-List for the fifth consecutive year and led the development of the world’s first pharmaceutical life cycle assessment standard, PAS 2090, aimed at reducing carbon footprints. In 2025, scope 1 and 2 greenhouse gas emissions decreased by 49% compared to 2019, while scope 3 emissions fell by 14%. The company’s renewable energy usage reached 86%. Additionally, Sanofi launched the "Cancer and Work" program to support affected employees, reflecting its commitment to social responsibility.
In terms of ESG ratings, Sanofi received an A rating from MSCI, a low risk score from Sustainalytics, and a 4.5/5 rating from FTSE4Good. These achievements align with the company’s vision of “Protecting Global Health,” as it drives sustainable healthcare through eco-friendly product design (e.g., optimized packaging for Dupixent and Toujeo).
